Clinical trial · no report yet · Phase 3
MEVPRO-2
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- NCT06629779 ↗
- Recruiting
- Pfizer
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| YouTube | 7 | |
| Podcasts | 3 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- PF-06821497; Placebo; Enzalutamide
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 900 (estimated)
- Primary outcomes
- Radiographic Progression Free Survival (rPFS)
- Sponsor
- Pfizer
- Start
- Oct 22, 2024
- Primary completion
- Dec 2, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06629779 · updated Oct 14, 2026
Publications
linked from the registry- Shore ND, Fizazi K, Schweizer MT, Castro E, Azad AA, George DJ, da Trindade KM, Zeng H, Shrivastava N, Tonkovyd S, Bock A, Nekkalapudi S, Tang Y, Lin S, Agarwal N. Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols. Future Oncol. 2026 May;22(12):1397-1408. doi: 10.1080/14796694.2026.2667441. Epub 2026 May 10. PubMed 42108644